Quarterly report · Q2
3055.TEDINET S100PK8H
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥129.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥248.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥122.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥759m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.1bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.7bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥1.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥140.6bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥136.9bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥137.0bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥83.9bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥81.3bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥56.6bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥55.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥55.4bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.4bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥21.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.4bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥22.6bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥122m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥224m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥633m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥849m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥648m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥62.94 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.94 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.44 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥52.06 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.17 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 40.3% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.5% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| Otherother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥30m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| Otherother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥910m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥6m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥40m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥848m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥217m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥631m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥20m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥33.0bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥32.7bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥251m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥777m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥172m |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥92.3bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥87.7bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥347m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥136.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥129.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.2bn |
| Otherother segments | revenue | 2021-04-01 → 2021-09-30 | ¥1.0bn |
| Otherother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥30m |
| Otherother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥991m |
| Otherother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥345m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥7m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥40m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥675m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥217m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥457m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥28m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥30.7bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥30.4bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥237m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥572m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥5m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥157m |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥87.2bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥82.8bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥113m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥128.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥122.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 550
| Item | Context | Value | Unit |
|---|---|---|---|
| Amortization of goodwill ope cf | Prior1YTDDuration | 55000000 | JPY |
| Amortization of goodwill ope cf | CurrentYTDDuration | 54000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YTDDuration | -38000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYTDDuration | -17000000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -151000000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -158000000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 0 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 0 | JPY |
| Equity in earnings losses of affiliates ope cf | Prior1YTDDuration | -55000000 | JPY |
| Equity in earnings losses of affiliates ope cf | CurrentYTDDuration | -54000000 | JPY |
| Loss gain on sales of noncurrent assets ope cf | Prior1YTDDuration | -51000000 | JPY |
| Loss gain on sales of noncurrent assets ope cf | CurrentYTDDuration | 0 | JPY |
| Loss on retirement of noncurrent assets ope cf | Prior1YTDDuration | 75000000 | JPY |
| Loss on retirement of noncurrent assets ope cf | CurrentYTDDuration | 1000000 | JPY |
| Loss gain on sales of investment securities ope cf | Prior1YTDDuration | -359000000 | JPY |
| Loss gain on sales of investment securities ope cf | CurrentYTDDuration | -389000000 | JPY |
| Impairment loss ope cf | Prior1YTDDuration | 2000000 | JPY |
| Impairment loss ope cf | CurrentYTDDuration | － | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | -386000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | -2843000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -654000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -1047000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 2169000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | 3098000000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | Prior1YTDDuration | 36000000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | CurrentYTDDuration | -270000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YTDDuration | -17000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYTDDuration | -14000000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YTDDuration | 161000000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYTDDuration | 160000000 | JPY |
| Increase decrease in provision for directors bonuses ope cf | Prior1YTDDuration | -67000000 | JPY |
| Increase decrease in provision for directors bonuses ope cf | CurrentYTDDuration | -73000000 | JPY |
| Decrease increase in accounts receivable other ope cf | Prior1YTDDuration | 102000000 | JPY |
| Decrease increase in accounts receivable other ope cf | CurrentYTDDuration | 715000000 | JPY |
| Increase decrease in deposits received ope cf | Prior1YTDDuration | -31000000 | JPY |
| Increase decrease in deposits received ope cf | CurrentYTDDuration | -34000000 | JPY |
| Other net ope cf | Prior1YTDDuration | -164000000 | JPY |
| Other net ope cf | CurrentYTDDuration | -136000000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 2860000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 1620000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 151000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 162000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -0 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -0 | JPY |
| Income taxes paid refund ope cf | Prior1YTDDuration | 69000000 | JPY |
| Income taxes paid refund ope cf | CurrentYTDDuration | -713000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 3081000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 1069000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -790000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -463000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |